Cardinal Well being Releases 2022 Biosimilars Report

Publication finds that solely about 40% of retail pharmacists really feel outfitted to debate biosimilars with sufferers

Pharma distributor Cardinal Well being printed itsĀ 2022 Biosimilars Report: The U.S. Journey and Path Forward, a publication that brings collectively the most recent trade knowledge on biosimilar utilization and payer protection with survey knowledge from healthcare suppliers, and ideas from physicians and specialists on biosimilars. The report supplies knowledge and insights on the place biosimilar adoption presently stands within the US and what’s anticipated in 2022 and past, as biosimilars come to market in key illness classes, together with diabetes and immunology.

The report options knowledge from biosimilar surveys consisting of greater than 320 oncologists, 100 rheumatologists, 100 retina specialists, 50 endocrinologists and first care physicians treating diabetes, and 115 retail pharmacists, performed in 2020 and 2021.

Among the many featured analysis are outcomes from a brand new insulin biosimilar survey with retail pharmacists exhibiting that solely about 40% really feel ready to debate biosimilars with sufferers. As well as, solely 20% of them be aware that they’re very accustomed to the FDA’s interchangeability designation, which permits them to substitute insulin biosimilars for reference biologics.

Different options of the report embody:

  • Payer protection developments of biosimilars by therapeutic space
  • The pipeline of biosimilars which are anticipated to launch within the US, 2022-2029
  • 5 biosimilar predictions for 2022

“2022 is ready to be a turning level within the US, as biosimilars develop into new therapeutic areas and websites of care, and reimbursement fashions proceed to evolve,” feedback Heidi Hunter, president of Cardinal Well being Specialty Options. “Our new biosimilars report demonstrates that, whereas market challenges stay, most healthcare suppliers have a robust curiosity in utilizing biosimilars to broaden affected person entry and drive extra inexpensive care for his or her sufferers.”

Supply hyperlink